首页> 美国卫生研究院文献>Journal of Biomedical Research >Screening of Fabry disease in patients with end-stage renal disease of unknown etiology: the first Thailand study
【2h】

Screening of Fabry disease in patients with end-stage renal disease of unknown etiology: the first Thailand study

机译:病因不明的终末期肾脏疾病患者的法布里疾病筛查:泰国第一项研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We aimed to explore the prevalence of Fabry disease in Thai patients who were diagnosed with end-stage renal disease (ESRD) of an unknown origin. Venous blood samples were collected from ESRD patients for biochemical and molecular studies. Alpha-galactosidase A (α-GAL A) screening was performed from dried-blood spots using fluorometry. Molecular confirmation was performed using DNA sequencing of the GLA gene. A total of 142 male and female patients were included in this study. Ten patients (7.04%) exhibited a significant decrease in α-GAL A activity. There were no definitive pathogenic mutations observed in the molecular study. However, four patients revealed a novel nucleotide variant at c.1 -10 C>T, which was identified as a benign variant following screening in the normal population. In conclusion, the α-GAL A assay utilizing dried-blood spots revealed a significant false positive rate. There was no definitive Fabry disease confirmed in Thai patients diagnosed with ESRD of unknown etiology.
机译:我们的目的是探讨被诊断患有未知来源的终末期肾病(ESRD)的泰国患者中法布里病的患病率。从ESRD患者中收集静脉血样本进行生化和分子研究。使用荧光法从干血斑中进行α-半乳糖苷酶A(α-GALA)筛选。使用GLA基因的DNA测序进行分子确认。本研究共纳入142名男性和女性患者。 10名患者(7.04%)的α-GALA活性显着降低。在分子研究中没有观察到确定的致病突变。然而,四名患者在c.1 -10 C> T处发现了一个新的核苷酸变异体,在正常人群中进行筛选后被鉴定为良性变异体。总之,利用干血斑的α-GALA分析显示出明显的假阳性率。在确诊为病因未知的ESRD的泰国患者中,没有确诊的Fabry病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号